Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia

American Journal of Hematology

Volumn 89, Issue 12, 2014, Pages E228-E234

  Mitchell, William Beau ^a,b   Pinheiro, Mariana P ^a   Boulad, Nayla ^a   Kaplan, David ^c   Edison, Michele N ^a   Psaila, Bethan ^a,d   Karpoff, Marissa ^a   White, Michael J ^e   Josefsson, Emma C ^e   Kile, Benjamin T ^e   Bussel, James B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c Pathfinder Biotech   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; PROTEIN BAK; PROTEIN BCL XL; PROTEIN KINASE B; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR; BAK1 PROTEIN, HUMAN; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; BENZOIC ACID DERIVATIVE; FC RECEPTOR; HYBRID PROTEIN; HYDRAZINE DERIVATIVE; MPL PROTEIN, HUMAN; PROTEIN BAX; PROTEIN BCL X; PYRAZOLE DERIVATIVE; THROMBOPOIETIN;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IN VIVO STUDY; MEGAKARYOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; AGONISTS; CASE CONTROL STUDY; CHRONIC DISEASE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BENZOATES; BLOOD PLATELETS; CASE-CONTROL STUDIES; CHRONIC DISEASE; GENE EXPRESSION REGULATION; HUMANS; HYDRAZINES; MEGAKARYOCYTES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; THROMBOPOIETIN;

EID: 84922394614     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23832     Document Type: Article

References (26)

1. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin North Am 2007;21:743-759, vii.
2. Barsam SJ, Psaila B, Forestier M, et al. Platelet production and platelet destruction: Assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 2011;117:5723-5732.
3. Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Curr Opin Hematol 2012;19:392-398.
4. Kaushansky K. Molecular mechanisms of thrombopoietin signaling. J Thromb Haemost 2009;7 (Suppl 1):235-238.
5. Josefsson EC, Dowling MR, Lebois M, Kile BT. The regulation of platelet life span. In: Michelson AD, editor. Platelets. London: Elsevier; 2013. pp 51-65.
6. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173-1186.
7. Kodama T, Takehara T, Hikita H, et al. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 2010;138:2487-2498, 2498.e2481-e2487.
8. Josefsson EC, James C, Henley KJ, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011;208:2017-2031.
9. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681.
10. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
11. Dasgupta SK, Argaiz ER, Mercado JE, et al. Platelet senescence and phosphatidylserine exposure. Transfusion 2010;50:2167-2175.
12. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009;114:663-666.
13. Vogler M, Hamali HA, Sun XM, et al. BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011;117:7145-7154.
14. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007;14:943-951.
15. Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;118:1663-1674.
16. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-496.
17. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149-1159.
18. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391-401.
19. de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L. STAT5-dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 2000;3:299-305.
20. Erhardt JA, Erickson-Miller CL, Aivado M, et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009;37:1030-1037.
21. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004;15:177-182.
22. Kaplan D, Smith D. Enzymatic amplification staining for flow cytometric analysis of cell surface molecules. Cytometry 2000;40:81-85.
23. Michel M, Kreidel F, Chapman E, et al. Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. Haematologica 2005;90:1715-1716.
24. Vandenberg CJ, Josefsson EC, Campbell KJ, et al. Loss of Bak enhances lymphocytosis but does not ameliorate thrombocytopaenia in BCL-2 transgenic mice. Cell Death Differ 2014;21:676-684.
25. Kelly PN, White MJ, Goschnick MW, et al. Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development. Cell Death Differ 2010;17:1655-1664.
26. Currao M, Balduini CL, Balduini A. High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes. PLoS One 2013;8:e54723.